Abstract:Belatacept, a high-affinity variant of CTLA4-Ig, is a recently approved immunosuppressive agent for the prevention of acute rejection. It functions as a potent antagonist of the CD28-B7 interactions, thereby inhibiting T cell co-stimulation and activation. Experimental data involving the transient use of CTLA4-Ig to induce allograft tolerance have shaped the current paradigm that CTLA-4Ig is ineffective at inhibiting memory T cell responses, and by extension T-dependent alloantibody responses. This resistance is explained by the acquisition of additional activation-induced costimulatory molecules by memory T cells. We noted that the efficacy of CTLA4-Ig as a continuously administered drug for controlling rejection in sensitized recipients has not been investigated. Here we report on the efficacy of CTLA4-Ig in preventing acute rejection in sensitized C57BL/6 recipients that had received BALB/c spleen cell transfusion 3-6 months previously. We set up four experimental groups. Group 1 (N=5): sensitized mice with HTX and CTLA4-Ig treated (Day -2, Day 0, Day2, then weekly (1 mg/dose) Group 2 (N=3): sensitized mice with HTX and no CTLA4-Ig, Group 3: (N=10) naive mice with HTX and CTLA4-Ig treated, Group 4 (N=10): naive mice with HTX and no CTLA4-Ig. In the untreated Groups 2 & 4, allografts were rejected within 7 days post-transplantation, whereas in Group 3 of naive mice receiving CTLA4-Ig, all the grafts survived long-term (>90 days). In Group 1 of sensitized recipients receiving CTLA4-Ig, the allografts survived for 42, 42, 49, >90, >90 days. The pre-transplant donor-specific antibody (DSA) titers in the recipients that went on to reject their graft was significantly higher compared to those that accepted their grafts. Furthermore, DSA titers increased post-transplantation in the recipients that went on to reject their allografts, whereas DSA titers decreased in those that accepted their grafts. In conclusion, these observations illustrate the efficacy of CTLA-4Ig treatment at controlling rejection in sensitized recipients, and underscore the barrier pre-transplantation DSA poses to long-term graft acceptance. This experimental model also provides a unique opportunity for testing if DSA promotes antibody-mediated rejection or alloreactive memory T cell priming and T cell-mediated rejection in CTLA4-Ig treated recipients, and for identifying therapies that promote long-term graft survival in sensitized recipients.

Induction of immunological tolerance to myelinogenic glial-restricted progenitor allografts

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

Regulatory T Cell Therapy for the Induction of Clinical Organ Transplantation Tolerance

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

Nanoparticles loaded with IL-2 and TGF-β promote transplantation tolerance to alloantigen

Guiding Postablative Lymphocyte Reconstitution as a Route Toward Transplantation Tolerance

Adoptive Transfer of IFN-γ-induced M-MDSCs Promotes Immune Tolerance to Allografts Through Inos Pathway.

Graft-Specific Regulatory T Cells for Long-Lasting, Local Tolerance Induction

An Immunotherapeutic Strategy for Prolonging Graft Survival in Mice.

Control of the Survival and Growth of Human Glioblastoma Grafted Into the Spinal Cord of Mice by Taking Advantage of Immunorejection

The potential of mesenchymal stem cells to induce immune tolerance to allogeneic transplants

Cfhr1-Modified Neural Stem Cells Ameliorated Brain Injury in A Mouse Model of Neuromyelitis Optica Spectrum Disorders

Twisting Immune Responses for Allogeneic Stem Cell Therapy.

Variegated levels of alloreactive T cell dysfunction in transplantation tolerance determine graft vulnerability to infection-triggered rejection

Effective Induction of Immune Tolerance by Portal Venous Infusion with IL-10 Gene-Modified Immature Dendritic Cells Leading to Prolongation of Allograft Survival

Permanent Acceptance of Mouse Cardiac Allografts with CD40 Sirna to Induce Regulatory Myeloid Cells by Use of a Novel Polysaccharide Sirna Delivery System

Anti-ICAM-1 Antibody and CTLA-4Ig Synergistically Enhance Immature Dendritic Cells to Induce Donor-Specific Immune Tolerance in Vivo

Functional Analysis of Alloreactive Memory CD4+ T Cells Derived from Skin Transplantation Recipient and Naïve CD4+ T Cells Derived from Untreated Mice.

Induction of Allospecific Tolerance by Immature Dendritic Cells Genetically Modified to Express Soluble Tnf Receptor

Challenges and promises in optimising a non-clinical protocol of intracerebroventricular human neural stem cell transplantation in ALS

Induction of immune tolerance for allogenic recipient mice by non-myeloablative bone marrow transplantation]